This article is more than 5 years old. Information may no longer be current.
Single-session short-duration pattern-scanning laser PRP may be appropriate for advanced diabetic retinopathy
Click Here to Manage Email Alerts
SAN FRANCISCO — Short-duration pattern-scanning laser panretinal photocoagulation completed in a single session can be recommended for patients with proliferative diabetic retinopathy with or without macular edema when clinically indicated, according to a study presented here.
However, “In severe nonproliferative diabetic retinopathy, divided session PRP would be preferable, even with a pattern scanning laser,” Edmund Y.M. Wong, MBBS, MMed, FRCS, FAMS, said in the presentation given at the American Society of Retina Specialists meeting.
“Overall, single-session complete panretinal photocoagulation with a short-duration pattern-scanning laser does induce a small increase in macular edema. This was especially [seen] in cases with severe nonproliferative diabetic retinopathy without pre-existing macular edema. The increase in post-laser macular edema was not significant in patients with pre-existing proliferative diabetic retinopathy with or without clinically significant macular edema,” Wong said.
The study, a prospective, masked, nonrandomized part of a larger prospective randomized clinical study comparing pattern-scanning laser panretinal photocoagulation (PSPRP) with standard argon laser PRP, included 24 patients. Study data showed PSPRP caused a small, significant increase in cube volume of 0.23 mm³, but should cause less collateral damage.
In cases of proliferative diabetic retinopathy or clinically significant macular edema, PSPRP did not result in increased macular edema. – by Robert Linnehan
Reference:
Wong EYM. Pattern scanning, single session, short-duration pan-retinal laser photocoagulation and the effect on macular edema in advanced diabetic retinopathy. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016; San Francisco.
Disclosure: Wong reports he is an investigator and a member of the speakers panel for Alcon, Bayer and Bausch + Lomb.